U.S. markets open in 23 minutes
  • S&P Futures

    4,133.50
    +26.50 (+0.65%)
     
  • Dow Futures

    34,077.00
    +139.00 (+0.41%)
     
  • Nasdaq Futures

    13,237.00
    +136.75 (+1.04%)
     
  • Russell 2000 Futures

    2,185.70
    +17.10 (+0.79%)
     
  • Crude Oil

    64.43
    +0.61 (+0.96%)
     
  • Gold

    1,838.00
    +14.00 (+0.77%)
     
  • Silver

    27.39
    +0.33 (+1.22%)
     
  • EUR/USD

    1.2134
    +0.0050 (+0.41%)
     
  • 10-Yr Bond

    1.6390
    -0.0290 (-1.74%)
     
  • Vix

    21.66
    -5.93 (-21.49%)
     
  • GBP/USD

    1.4081
    +0.0029 (+0.21%)
     
  • USD/JPY

    109.3800
    -0.0540 (-0.05%)
     
  • BTC-USD

    50,293.13
    +12.05 (+0.02%)
     
  • CMC Crypto 200

    1,396.80
    +8.89 (+0.64%)
     
  • FTSE 100

    7,014.69
    +51.36 (+0.74%)
     
  • Nikkei 225

    28,084.47
    +636.46 (+2.32%)
     

Have Insiders Been Buying BioCardia, Inc. (NASDAQ:BCDA) Shares?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So we'll take a look at whether insiders have been buying or selling shares in BioCardia, Inc. (NASDAQ:BCDA).

Do Insider Transactions Matter?

It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, rules govern insider transactions, and certain disclosures are required.

Insider transactions are not the most important thing when it comes to long-term investing. But it is perfectly logical to keep tabs on what insiders are doing. For example, a Columbia University study found that 'insiders are more likely to engage in open market purchases of their own company’s stock when the firm is about to reveal new agreements with customers and suppliers'.

View our latest analysis for BioCardia

The Last 12 Months Of Insider Transactions At BioCardia

Over the last year, we can see that the biggest insider purchase was by Independent Director Simon Stertzer for US$300k worth of shares, at about US$2.10 per share. We do like to see buying, but this purchase was made at well below the current price of US$4.34. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

Over the last year, we can see that insiders have bought 437.75k shares worth US$920k. But insiders sold 11.64k shares worth US$24k. Overall, BioCardia insiders were net buyers during the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

BioCardia is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that BioCardia insiders own 38% of the company, worth about US$21m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At BioCardia Tell Us?

It doesn't really mean much that no insider has traded BioCardia shares in the last quarter. On a brighter note, the transactions over the last year are encouraging. Overall we don't see anything to make us think BioCardia insiders are doubting the company, and they do own shares. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To help with this, we've discovered 4 warning signs (2 make us uncomfortable!) that you ought to be aware of before buying any shares in BioCardia.

But note: BioCardia may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.